Please assess the completion status of the following clinical trial:

Trial Title: Effect of Aspirin, Hemodilution and Desmopressin on Platelet Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 60 adult Chinese subjects aged 18-60 without known platelet disorder, thrombocytopenia, history of taking drugs that may affect platelet function including herbal preparations.~Exclusion Criteria:~1. Any known platelet or coagulation disorder~2. Expected surgical operation or dental treatment within one week of scheduled drug intake.~3. Known peptic ulcer disease~4. Obesity (BMI \>=30)~5. Pregnant or lactating women.~6. Known chronic liver or renal disease.~7. Coronary artery, carotid artery or peripheral artery disease~8. Recent history of taking antiplatelet drugs, anticoagulants or herbal preparations.~9. Smoker or alcohol user~10. Mentally incapable of providing informed consent~11. Students or junior staff members who had direct working relationship with the PI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Placebo group (Type: PLACEBO_COMPARATOR): Subjects will be given placebo daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15 microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.
- Aspirin group (Type: ACTIVE_COMPARATOR): Subjects will be given aspirin 100mg daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).